

Supplementary Figure S1: Gating strategy phenotype. Analysis of CD56<sup>+</sup> CD3<sup>-</sup> NK cells, CD56<sup>bright</sup> NK cells, and CD56<sup>dim</sup> NK cells is shown for activating and inhibitory surface receptors in a Graves' subject (CD16, CD69, NKG2D, NKG2A, NKp30, and CD161).

Supplementary Figure S2: Gating strategy degranulation. Analysis for CD56<sup>+</sup> CD3<sup>-</sup> NK cells, CD56<sup>bright</sup> NK cells, and CD56<sup>dim</sup> NK cells is shown for CD107a marker with or without K562 in a Graves' subject.

Supplementary Figure S3: Gating strategy intracellular cytokine. Analysis for CD56<sup>+</sup> CD3<sup>-</sup> NK cells, CD56<sup>bright</sup> NK cells, and CD56<sup>dim</sup> NK cells is shown for IFN $\gamma$  and TNF $\alpha$  in a Graves' subject.